Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States

References

• D’Amato G, Steinert DM, McAuliffe JC, et al. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44–56
   PubMedGoogle Scholar
• Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992-2000. Am J Gastroenterol 2005;100:162–68
   PubMed Web of Science ®Google Scholar
• Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 2005;103:821–29
   PubMed Web of Science ®Google Scholar
• Bümming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006;93:836–43
   PubMed Web of Science ®Google Scholar
• Rubin J, Sanon M, Taylor D, et al. Epidemiology, survival, and costs of localized gastrointestinal stromal tumors. Int J Gen Med 2011;14:121–30
   Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–8
   PubMed Web of Science ®Google Scholar
• Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045–52
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466–78
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetric GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620–5
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459–65
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;28:097–104
   Google Scholar
• Joensuu, et al. Twelve vs. 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition).Vol 29, No 15_suppl (May 20 Supplement), 2011: LBA1.
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322–38
   PubMed Web of Science ®Google Scholar
• Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(2 Suppl):S1–S29
   Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127–34
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329–38
   PubMed Web of Science ®Google Scholar
• Contreras-Hernández I, Mould-Quevedo JF, Silva A, et al. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. Br J Cancer 2008;98:1762–8
   PubMed Web of Science ®Google Scholar
• National Vitals Statistics Report. United States Life Tables Report 2004. http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_09.pdf. Accessed September 1, 2008
   Google Scholar
• Huse DM, von Mehren M, Lenhart G, et al. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig 2007;27:85–93
   PubMed Web of Science ®Google Scholar
• Heintz D, Noronha-Jackson A, Green S, et al. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk for recurrence: a randomized Phase III study. Trial Study report- data on file Novartis.
   Google Scholar
• Wilson J, Connock M, Song F, et al. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation. Health Technol Assess 2005;9:1–142
   PubMed Web of Science ®Google Scholar
• Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 2008;44:972–7
   PubMed Web of Science ®Google Scholar
• Hanmer J, Lawrence W, Anderson J, et al. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality of life scores. Med Decis Making 2006;26:391–400
   PubMed Web of Science ®Google Scholar
• Drug topics red book. Montvale, NJ: Thomson Healthcare, 2010.
   Google Scholar
• Physician’s Fee and Coding Guide, Volume 1. Duluth, GA: MAG Mutual Healthcare Solutions, Inc, 2010.
   Google Scholar
• DRG Expert. 24th ed. Ingenix, 2010.
   Google Scholar
• Measuring price change for medical care in the CPI. http://www.bls.gov/cpi/cpifact4.htm. Accessed July 13, 2011.
   Google Scholar
• Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(2 Suppl):ii35–8
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Glivec in the treatment of unresectable and/or metastatic KITpositive gastrointestinal stromal tumours (GISTs) in the United Kingdom: a submission to the National Institute for Clinical Excellence. 2003.
   Google Scholar
• Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630–41
   PubMed Web of Science ®Google Scholar
• Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90–5
   PubMed Web of Science ®Google Scholar